Affordable Access

Phase II evaluation of anguidine (NSC-141537) for adenocarcinoma of the colon or rectum.

Authors
Type
Published Article
Journal
Cancer clinical trials
Publication Date
Volume
1
Issue
4
Pages
297–299
Identifiers
PMID: 757146
Source
Medline

Abstract

Anguidine was administered in a dose of 5.0 mg/m2 (3.5 mg/m2 for patients with hepatic dysfunction) intravenously daily for 5 days in a phase II evaluation of 19 patients with metastatic adenocarcinoma of the colon or rectum. Courses were repeated every 3 weeks. No responses were observed but five patients had disease stabilization. Toxicity was marked, causing discontinuation of therapy in several patients. Anguidine appears ineffective in patients with metastatic colon or rectal cancer in the dose and schedule used in this study.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments